Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Bestell Offices Designated Bestell Offices Designated Bestell Designated B Approved for use through 3/31/2007. OMB 0651-0021 ATTORNEY'S DOCKET NUMBER U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE 21494YP TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 15 August 2003 PCT/US2004/025961 11 August 2004 TITLE OF INVENTION 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS APPLICANT(S) FOR DO/EO/US Wayne Thompson, Steven D. Young, Brian T. Phillips, Peter Munson, Willie Whitter, Nigel Liverton, Christine Dieckhaus, John Butcher, John A. McCauley, Charles J. McIntyre, Mark E. Layton, Philip E. Sanderson Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must 3. include items (5), (6), (9) and (21) indicated below. The US has been elected (PCT Article 31). A copy of the International Application as filed [35 U.S.C. 371(c)(2)] a. is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. c. X is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau). b. L have been communicated by the International Bureau. c. La have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)]. Article 36 [35 U.S.C. 371(c)(5)]. Items 11 to 20 below concern other document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 18. A second copy of the published International Application under 35 U.S.C.154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).

Other items or information:

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"

Approved for use through 3/31/2007. OMB 0651-0021

U.S. APPLICATION NO. (If known, seg 37 CFR 1.5)			INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER				
() () () () () () () () () ()			PCT/US2004/025961			21494YP				
The following f	ees are s	CALCULATIONS	PTO USE ONLY							
					\$300			\$300.00		
22. Examination fee (37 CFR 1.492(c))										
If the written opinion prepared by ISA/US or the international preliminary examination report										
prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)								\$0.00		
		\$0.00								
23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by										
IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0										
Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an										
International Searching Authority								\$0.00		
previously communicated to the US by the IB\$400										
All other situations\$500										
TOTAL OF 21, 22 and 23=								\$300.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
			Number	of each additional 50 or fraction						
Total Sheets	Extra	Sheets			to a whole number)		RATE			
151 - 100 =	51	/50	1.02		2	X	\$250.00	\$500.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].										
CLAIMS		NUMBER	FILED		NUMBER EXTRA		RATE			
Total Claims			17	- 20 =	0	х	\$50.00	\$0.00		
Independent Claims			5	- 3 =	2	Х	\$200.00	\$400.00		
•					2		_	\$100,00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00								\$1,200.00		
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) = \$1,200.00										
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)].									,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
TOTAL NATIONAL FEE =								\$1,200.00		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.										
accompanied by an appropriate cover silect (57 CFR 2				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	TOTAL FEES ENCLOSED =			\$1,200.00		
							····			
								Amount to be		
							refunded:			
							Amount to be charged:			
			•			1	1	charged.		
a. A check in the amount of \$ to cover the above fees is enclosed. Deposit Account No. 13-2755 in the amount of \$1,200.00 to cover the above fees.										
A duplicate copy of this sheet is enclosed.										
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or										
(b)] must be filed and granted to restore the International Application to pending status.										
SEND ALL CORRESPONDENCE TO:										
Customer No. 000210										
MERCK & CO., INC.										
Patent Department, RY60-30							MA We "			
P.O. Box 2000 SIGNATURE										
126 East Lincoln Avenue Rahway, New Jersey 07065-0970 Mittal L Decei										
Mitul 1. Desai										
NAME NATE: February 14, 2006										
DATE: <u>February 14, 2006</u> 46,661										
PHONE #: (732) 594-3190						REGISTRATION NUMBER				

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	21494YP					
International Appln No.:	PCT/US2004/025961					
International Filing Date:	11 August 2004					
Priority Date:	15 August 2003					
Title:	4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS					
Inventors:	Wayne Thompson, Steven D. Young, Brian T. Phillips, Peter Munson, Willie Whitter, Nigel Liverton, Christine Dieckhaus, John Butcher, John A. McCauley, Charles J. McIntyre, Mark E. Layton, Philip E. Sanderson					

21494YP

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT February 14, 2006

EXPRESS MAIL NO. EV 660605561 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS JP.O. BOX 1450, ALEXANDRIA, YIRGINIA 22313-1450.

MAILED BY